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Background: Higher dose of vitamin D supplementation 50000 IU is required for those whose serum 25(OH)D
levels are 50 nmol/L and below. The increment in serum 25(OH)D though not significantly affected by race, sex or
age it is negatively correlated to the baseline 25(OH)D concentration. This study investigated whether the mean
increase in serum 25(OH)D will be higher among participants with lower baseline 25(OH)D levels and whether the
duration of supplementation has an influence on the serum 25(OH)D achieved.
Methods: A clinical audit of patients’ medical records from a community health centre in Melbourne for the period
01.01.2010 to 31–12.2012 was undertaken. Paired sample t test was used to determine difference in pre and post
dose serum 25(OH)D. Simple and multiple linear regressions were used to examine the association between the
difference in pre and post dose serum 25(OH)D and duration of supplementation and baseline serum 25(OH)D,
adjusting for socio-demographic factors.
Results: A total of 205 patients were included in the study. Mean difference in serum 25(OH)D was highest 52.
8 nmol/L (95 % CI: 46.63–58.92) among those whose serum 25(OH)D was below 25 nmol/L at baseline. Baseline
25(OH)D alone accounted for 13.7 % of variance in the effect size (F(2, 202) = 16.0. p < 0.001), with the effect size
significantly higher among participants with a baseline 25(OH)D level of 25–49 nmol/L (β = 11.93, 95 % CI: 0.48, 23.
40, p < 0.05). Mean serum 25(OH)D difference was highest, 47.53 nmol/L (95 % CI: 40.95–54.11) when measured
within 3 months of supplementation. Duration of supplementation explained 2.9 % of the variance in the effect size
(F (1, 203) = 6.11, p < 0.05) and there was an inverse relationship between the length of supplementation and mean
pre and post supplementation serum 25(OH)D difference (β = −1.45, 95 % CI: −2.62, −0.29, p = 0.014).
Conclusion: Following 50000 IU vitamin D3 for 12 months mean serum 25(OH)D increase was highest among
those whose baseline serum 25(OH)D was lower. Migrants especially dark-skinned are at a high risk for vitamin D
deficiency in Australia. High dose vitamin D3 50000 IU (cholecalciferol) is effective in achieving sufficient serum
25(OH)D among these populations who tend to have lower baseline serum 25(OH)D.
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Vitamin D deficiency (VDD) is a significant public health
issue worldwide. VDD is commonly defined as serum
25(OH)D below 50 nmol/L [1]. While there have been dif-
ferent cut-off points proposed to define VDD, the widely
accepted is that of Endocrine society, International osteo-
porosis and US department for health which proposed that
serum 25(OH)D levels should be greater than 75 nmol/L
particularly in older adults [2–5]. Low levels of vitamin D
have been found to be associated with deleterious health
including increased risk for fractures, functional limita-
tions and chronic diseases [2]. More recently low vitamin
D has been linked to mental health conditions including
schizophrenia, altered immunity and other autoimmune
diseases [6].
However VDD is unequally distributed and those with
dark skinned population in high Northern 37° N or low
Southern 37° S latitudes seem to be affected more than
light skinned population [7, 8]. VDD is common in immi-
grant groups from developing countries living in western
countries, including Northern Europe, USA and Australia
[9]. Possible risk factors for the high levels of VDD include
dark skin and decreased sun exposure after settling in the
host country [10].
Although sun is the main source of vitamin D, produc-
tion of vitamin D is influenced by the season, latitude,
[7] skin colour and skin exposure [11]. Vitamin D3 is
found naturally in small quantities such as oily fish, eggs
and fortified foods such as margarine and some low-fat
milk products [12]. Therefore ongoing supplements may
be necessary for people at high risk of vitamin D defi-
ciency [13].
While vitamin D supplementation is needed to achieve
a desired threshold of serum 25(OH)D concentrations
among deficient individuals, there is no universally ac-
cepted threshold at which initiating vitamin D supplemen-
tation would achieve the greatest impact. In Victoria,
Australia for those whose serum levels are 50 nmol/L and
below recommendations are to supplement with higher
dose 50000 IU per month and serum 25(OH)D to be
rechecked after 3 months and then at 12 months [6] as it
takes 3–5 months for serum 25(OH)D to plateau [14, 15].
Although the incremental increase in serum 25(OH)D is
not significantly affected by race, sex or age it is negatively
correlated to the baseline 25(OH)D concentration [14, 16].
In a study by Trang et al. subjects taking 4000 IU vitamin
D2 or vitamin D3, the effect of vitamins D2 and D3 at in-
creasing serum 25(OH)D concentrations diminished pro-
gressively at above 50 nmol/L basal 25(OH)D [17]. There is
little evidence for the effect of high dose vitamin D supple-
mentation on the increase in serum 25(OH)D at lower
baseline serum 25(OH)D levels. Therefore the aim of this
study was to examine whether the effect of 50,000 IU vita-
min D3 once a month over 12 months would be greateramong subjects with lower baseline 25(OH)D (<50 nmol/L)
than those with higher baseline 25(OH)D (>50 nmol/L)
and whether this was dependent on the length of treatment.
We hypothesised that 1) post vitamin D supplementa-
tion change in serum 25(OH)D levels will be greater
among participants with lower baseline 25(OH)D levels
and 2) increase in serum 25(OH)D levels will be inversely
proportional to the length of vitamin D supplementation.Method
Design and setting
The study was a retrospective audit of medical records.
The study design has been described elsewhere [18–20].
Briefly an audit of patient records at a major metropol-
itan community health centre in the western region of
Melbourne was undertaken. The centre provides pri-
mary, community and specialist mental health services
to the people across the City of Melbourne and Moonee
Valley City Council. Of these 48 % from the City of
Melbourne and 23 % from Moonee Valley City were
born overseas [21]. The centre offers health assessment
for immigrants arriving as family migrants, asylum
seekers and refugees with the vast majority arriving from
Asia, Africa and Middle Eastern countries.Inclusion criteria and Vitamin D supplementation protocol
Our initial contact with the health practitioners was in
2013 and we chose to include all adults aged 18 years and
above who attended the health centre between 01.01.2010
and 31.12.2012. The intent of 3 years time frame was to
include a representative sample of the migrant population
who attended the community centre for the initial health
assessment and follow up. Inactive patients such as de-
ceased and those patients who had not recorded their
country of birth during registration were excluded from
the study.
Only those who were prescribed a high dose 50,000 IU
Vitamin D3, had serum 25(OH)D measured both pre and
post vitamin D supplementation was included in the study.
Individuals who had serum 25(OH)D below 50 nmol/L
were prescribed a high dose 50000 IU vitamin D3. How-
ever few individuals whose serum 25(OH)D was above
50 nmol/L were also supplemented with 50000 IU vitamin
D3. Patients were prescribed one capsule of 50000 IU vita-
min D3 for 12 months. However, those individuals whose
serum 25(OH)D was below 25 nmol/L one 50000 IU vita-
min D3 capsule per week for 4 weeks followed by one cap-
sule per month was prescribed. Of the 2,187 patients,
1,217 had serum vitamin D measured in the time period
(01.01.2010–31.12.2012) covered by the audit. A total of
205 patients met our inclusion criteria and was included
in the study.
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The primary outcome was the post serum 25(OH)D levels
following vitamin D supplementation and mean serum
25(OH)D difference in pre and post vitamin D
supplementation.Independent variables
Baseline 25(OH)D
For each patient, serum 25(OH)D and the date of test
recorded in the electronic database was obtained. Names
of the laboratories which undertook patients’ vitamin D
testing was obtained from the patients’ database. Infor-
mation on the biochemical assay used in the analysis of
serum 25(OH)D was obtained from the referring labora-
tories. Vitamin D testing was predominantly undertaken
by a single pathology which used Diasorin immunoassay
for measuring serum 25(OH)D of the patients.
For the purpose of this study following classification was
used: vitamin D sufficiency > 75 nmol/L; sub-optimal levels
50–75 nmol/L; vitamin D insufficiency 25–50 nmol/L,
moderate vitamin D deficiency 15–25 nmol/L, and severe
vitamin D deficiency < 15 nmol/L [22]. Due to small
sample size in cells we combined the sufficiency and
suboptimal groups as suboptimal-to-sufficient levels
(50–75 nmol/L) and severe deficiency and moderate defi-
cient groups were categorised as moderate-to-severe defi-
cient group (<25 nmol/L).Duration of treatment
The number of days between the date of supplementa-
tion and the first post dose serum 25(OH)D test within
12 months period was considered as the duration of
vitamin D supplementation. Since our audit was for a
three year period the date of vitamin D supplementa-
tion varied across the population.Socio-demographic variables
In our recent study we found that vitamin D deficiency
post-migration was closely linked with the region of ori-
gin [18]. Therefore it was important to control for mi-
gration status. We obtained country of birth for each
patient that was recorded at the time of patients’ registra-
tion at the health centre. The patients were classified as
Migrant (those born overseas) and Non migrant (those
born in Australia). Similarly, various studies have found
that the prevalence of vitamin D deficiency increases sig-
nificantly with age and are greater in women [23]. The ef-
fect of age and gender was controlled for in our analysis.
Date of birth and gender for each patient was obtained
from the medical record. The patients were classified into
following age groups; 18-34 years, 35-54 years and those
above 55 years [24].Data analysis
Data was analysed using STATA 12 (Stata, Texas). To ac-
count for the seasonal variation in serum 25(OH)D adjusted
serum 25(OH)D was computed using the formula: [25]
Adjusted vitamin D ¼ ðLog vit Dð Þ þ ½overall mean log vit Dð Þ
−mean log vit Dð Þ sampled in
same monthÞ
Paired sample t test was used to determine the differ-
ence in pre and post dose serum 25(OH)D. Simple and
multiple linear regressions were used to examine the asso-
ciation between the difference in pre and post dose serum
25(OH)D and duration of supplementation and baseline
serum 25(OH)D, adjusting for socio-demographic factors.
Results
The study included 205 participants of whom only 11.7 %
had suboptimal level-to-sufficient (50–75 nmol/L) serum
25(OH)D, 45.85 % had insufficient (25–49 nmol/L) serum
25(OH)D and 42.44 % were classified as moderate-to-
severe (<25 nmol/L) vitamin D deficient (Table 1). The
average age of the study population was 43.89 ± 15.36 years
and the average duration between the date of supplementa-
tion and the date of first post dose vitamin D testing was
5.73 ± 3.22 months.
At baseline, more than three quarters (>85 %) of par-
ticipants had serum levels below 50 nmol/L. Following
vitamin D supplementation, the post supplementation
serum 25(OH)D averaged 82.7 ± 22.48 nmol/L, 71.37 ±
23.35 nmol/L and 70.4 ± 20.19 nmol/L among partici-
pants whose serum 25(OH)D at baseline was 50–
75 nmol/L, 25-49 nmol/L and below 25 nmol/L respect-
ively. At 3 months post vitamin D supplementation, serum
25(OH)D was 75.74 ± 24.02 nmol/L and at 4–6 months
serum 25(OH)D was 74.70 ± 24.90 nmol/L. Rise in serum
25(OH)D levels was lower at 7–9 months measuring
68.89 ± 25.51 nmol/L and 65.00 ± 31.47 nmol/L when
measured at 10–12 months (Table 1).
Effect size
The overall effect size (mean difference of 25(OH)D be-
tween post and pre supplementation) of the vitamin D
supplementation of 50,000 IU was 41.9 nmol/L (95 %
CI: 38.1, 45.6). Post treatment, the mean difference in
serum 25(OH)D was highest 52.8 nmol/L (95 % CI:
46.63–58.92) among those whose serum 25(OH)D was
below 25 nmol/L at baseline followed by those between
25–49 nmol/L which was 36.3 nmol/L (95 % CI:31.48–
41.08) and 24 nmol/L (95 % CI:16.54–32.15) among those
who had serum 25(OH)D between 50–75 nmol/L at base
line (Table 1). Baseline 25(OH)D alone accounted for 13.7 %
of variance in the effect size (F(2, 202) = 16.0. p < 0.001), with
the effect size significantly higher among participants with a
baseline 25(OH)D level of 25–49 nmol/L (β= 11.93, 95 %
Table 2 Multiple linear regression for the predictors of mean
serum 25OHD difference following vitamin D supplementation
Variables Unadjusted Adjusted
β 95 % CI β 95 % CI
Serum 25(OH)D Category
50-75 nmol/L Ref
25-49 nmol/L 11.83* 0.48–23.39 12.73* 1.16–4.30
Below 25 nmol/L 28.43*** 16.88–39.98 28.40*** 16.73–40.08
Duration of Supplementation
(Months) −1.45* −2.62–-0.29 −1.18* −2.29–-0.06
Age (years) −0.016 −0.26–0.22 0.09 −0.15–0.33
Gender
Female Ref
Male 3.62 −4.33–11.59 4.52 −3.02–12.07
Migrant status
Non migrant Ref
Migrant 4.70 −3.69–13.11 1.87 −6.60–10.35
*p < 0.05; ***p < 0.001
Table 1 Mean serum 25(OH)D difference for pre and post vitamin D supplementation across all demographic characteristics





95 % Class Interval
P value
All 205 (100) 30.39 (14.43) 72.27 (26.06) 41.88 (38.14–45.63) <0.05
Serum 25 OHD Category
50–75 nmol/L 24(11.70) 58.22 (8.66) 82.57(22.48) 24.34(16.54–32.15) <0.05
25–49 nmol/L 94(45.85) 35.08 (6.68) 71.37(23.35) 36.28 (31.48–41.08) <0.05
Below 25 nmol/L 87(42.43) 17.63 (4.56) 70.41 (20.19) 52.77 (46.63–58.92) <0.05
Duration of Supplementation
3 months and below 64(31.21) 28.21(13.04) 75.74(24.02) 47.53(40.95–54.11) <0.05
4–6 months 66(32.19) 32.13(14.54) 74.70(24.94) 42.57(35.58–49.96) <0.05
7–9 months 42(20.48) 28.92(15.08) 68.89(25.51) 39.90(31.83–47.97) <0.05
10-12 months 33(16.09) 32.92(15.13) 65.00(31.47) 32.08(22.81–41.35) <0.05
Age Category
18–34 70(34.14) 28.64(12.87) 70.26(28.46) 41.79(35.51–48.08) <0.05
35–54 79(38.53) 28.67(14.08) 70.58(24.72) 41.80(35.86–47.75) <0.05
55 and above 56(27.31) 35.20(15.83) 77.32(24.89) 42.11(34.19–50.03) <0.05
Gender
Female 137(66.82) 30.35(15.38) 71.03(26.61) 40.68(36.05–45.31) <0.05
Male 68 (33.17) 30.47(12.39) 74.78(24.92) 44.31(37.82–50.80) <0.05
Migrant status
Non migrant 56 (27.31) 34.34(14.26) 72.81(26.68) 38.46(30.68–46.24) <0.05
Migrant 149(72.68) 28.90(14.26) 72.02(25.91) 43.17(38.88–47.45) <0.05
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28.43, 95 % CI: 16.88, 39.98, P < 0.001) than those with
50–75 nmol/L (Table 2). These results remained consistent
after controlling for duration of treatment, gender, age,
and migration status (Table 2). Mean serum 25(OH)D
difference was highest, 47.53 nmol/L (95 % CI: 40.95–
54.11) when measured within 3 months of supplementa-
tion, 42.57 nmol/L (95 % CI:35.58–49.96) at 4–6 months,
39.90 nmol/L (95 % CI:31.83–47.97) at 7–9 months and
lowest when measured at 10–12 months 32.08 nmol/L
(95 % CI:22.81–41.35) (Table 1). Duration of supple-
mentation explained 2.9 % of the variance in the ef-
fect size (F (1, 203) = 6.11, p < 0.05). That is, there was
an inverse relationship between the length of supplemen-
tation and mean pre and post supplementation serum
25(OH)D difference (β = −1.45, 95 % CI: −2.62, −0.29,
p = 0.014). These results remained consistent after
controlling for baseline 25(OH)D level, gender, age, and
migration status (Table 2). The effect of age, gender, and
migration status was negligible and non-significant.
Discussion
To the best of our knowledge this is the first retrospective
study in Australia to examine the effect of high dose,
50000 IU oral vitamin D3 (cholecalciferol) supplementation
on mean serum 25(OH)D among migrant and non migrant
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relationship between pre-supplementation serum 25(OH)D
and the pre-and post vitamin D supplementation mean
serum difference in 25(OH)D was confirmed.
Studies evaluating effect of high dose vitamin D on
serum 25(OH)D are limited. However, our findings are
similar to those reported by Talwar et al. [26] and Garrett-
Mayer and colleagues [27]. For example, Garrett-Mayer
and colleagues [27] undertook a study among African and
white men who were treated with 4000 IU/day for 1 year.
Participants in both the groups had serum 25(OH)D
below 50 nmol/L at baseline. Participants with the lowest
baseline serum 25(OH)D had the largest increase by
2 months [27]. Similar inverse association for baseline
serum 25(OH)D and increase in serum 25(OH)D was seen
among young and old men following vitamin D supple-
mentation 800 IU/day for 8 weeks [16]. According to
Heany et al. [28] the concentration of serum 25(OH)D in
response to vitamin D3 is biphasic, that is, a rapid increase
occurs at low vitamin D3 concentrations and a slower re-
sponse occurs at higher concentrations.
We also hypothesised that the post-vitamin D supple-
mentation 25(OH)D levels will be inversely associated
with the length of supplementation. This hypothesis was
confirmed, but the effect was significantly smaller than that
associated with baseline 25(OH)D levels. This finding is in-
consistent with the literature. In an observational study by
Shab-Bidar et al. [29] the effects of increasing doses
(400 IU, 800 IU, 1700 IU and 3500 IU/day) of vitamin D3
at lower baseline serum 25(OH)D values on the serum
25(OH)D was determined. They reported that the increase
in mean serum 25(OH)D was higher, 24.3 ± 34.0 nmol/L
after 11 months of supplementation compared to mean
serum 25(OH)D, 17 ± 32 nmol/L after 4 months of supple-
mentation. However unlike the study by Shab-Bidar et al.
[29] where the same group of patients were followed at
4 months and 11 months period, we reported mean serum
difference for those who were tested within 3 months, 4–6
months, 7–9 months and 10–12 months of vitamin D sup-
plementation. Shab-Bidar et al. undertook meta-regression
analysis based on randomized clinical trials (RCTs) in
adults to review the influence of supplementation-related
factors (dose and duration) and patient-related factors (age
and baseline 25[OH]D) on changes in serum levels of
25(OH)D [30]. An immediate increase in pooled mean dif-
ference of serum 25(OH)D was found in patients with
baseline <50 nmol/L reaching a plateau after 6 months in-
dicating substantial increase in serum 25(OH)D within few
months of vitamin D supplementation.
Possible factors influencing the mean serum difference at
different time intervals in our study could be the noncom-
pliance of the patients with regards to vitamin D supple-
mentation. Due to retrospective nature of this study we did
not have information on the patients’ compliance with thevitamin D supplementation. Moreover individuals in our
study whose serum 25(OH)D was below 25 nmol/L at
baseline were prescribed one 50000 IU vitamin D3 per
week for a month followed by one per month. This dispar-
ity in dosing regimen might have resulted in a higher serum
25(OH)D achieved within 3 months and also by those
whose serum 25(OH)D was below 25 nmol/L at baseline.
In a randomized dose response study among UK male ath-
letes, 17 out of 30 (57 %) had mean serum levels 51 ±
24 nmol/L at baseline, of which 20 % (6 out of 30) were
classified as deficient or severely deficient. Supplementation
with 40000 IU vitamin D3 per week for 6 weeks resulted in
higher serum 25(OH)D, 98 ± 14 nmol/L compared to those
who were supplemented with 20000 IU vitamin D3 per
week, 79 ± 14 nmol/L [31]. However there was no signifi-
cant difference in serum levels after 12 weeks of supple-
mentation with both groups achieving serum 25(OH)D
above 75 nmol/L i.e. 91 ± 24 nmol/l (40000 IU) and 85 ±
10 nmol/L (20000 IU). This study further reported that
there was no additional advantage of 40000 IU/week for a
target serum of 75 nmol/L. Whether this implies to our
study is unclear due to the diverse population which in-
cluded migrants, non migrants, different age groups, men
and women unlike the previous study [30] which included
only active male athletes.
Patient disease state such as gastrointestinal abnormal-
ities, kidney and liver disease also affects the metabolism of
vitamin D [32]. It has been emphasized that the genetic
make-up of subjects may play an important role in that sub-
jects with different vitamin D binding protein (DBP) geno-
types have different responses to the same vitamin D dose
[33]. Although only those individuals in our study whose
serum 25(OH)D was 50–75 nmol/L at baseline achieved
serum 25(OH)D above 75 nmol/L,individuals whose serum
25(OH)D was below 50 nmol/L achieved an average seru-
m25(OH)D levels of 70 nmol/L. Thus 50000 IU vitamin D3
supplementation for 12 months was effective in achieving
vitamin D sufficiency i.e. serum 25(OH)D above 50 nmol/L
among VDD adult population.
Findings from our study showed that supplementation
with high dose i.e. 50000 IU of vitamin D3 cholecalcif-
erol restored serum levels to sufficient levels i.e. above
50 nmol/L among migrants and non migrants especially
for those who have lower baseline serum 25(OH)D. Mi-
grants especially those who are dark skinned have a
higher prevalence of vitamin D deficiency (<50 nmol/L)
in Australia [34–36]. Therefore high-dose oral cholecal-
ciferol may be more practical and cost-effective than low
dose regimen in treating VDD. The cost of high dose
50000 IU vitamin D3 is $20 for 10 tablets while the cost
of the low-dose supplements is about $30 for 300 cap-
sules at retail pharmacies in Australia [37].
Our study found that the pre and post vitamin D sup-
plementation mean difference in serum 25(OH)D did
Gowda et al. BMC Health Services Research  (2016) 16:579 Page 6 of 7not vary by migration status, age, and gender. A study in
Britain among adults aged 65–85 both males and females
achieved similar serum 25(OH)D 75.6 and 72 nmol/L fol-
lowing vitamin D supplementation of 100,000 IU/
4 months for 5 years [38]. Aloia et al. in their study among
18–65 years found no significant sex differences on serum
25(OH)D in response to vitamin D among black and
whites males and females [14]. In contrast, various studies
have reported the influence of age. For example in Harris
et al. [16] the magnitude of change in serum 25(OH)D
after 8 weeks of 800 IU Vitamin D supplementation was
almost similar, 22.5 nmol/L and 22.1 nmol/L in the young
and the old men respectively. In a cross sectional study of
Chinese men, mean serum 25(OH) D levels was highest
among participants aged from 40 to 59, while it was low-
est in the 20–39 age groups [39]. The precise vitamin D
dose taken by the participants were unknown, they were
stated as taking vitamin D >250 IU/day. Whether differ-
ences in the sun exposure behaviour among the old and
young men (working indoors) accounted for variations in
serum 25(OH)D levels was not clear.
Limitations
Due to the retrospective nature of the study, our findings
may have been influenced by potential confounding factors.
We did not have the data for Body Mass Index (BMI) on
all patients hence this variable was not included in our
study. Obesity has been associated with decreased bioavail-
ability of dietary vitamin D [32]. Lack of information on
outdoor activities, clothing style whether patients fully cov-
ered their skin with clothing or not when they were in the
sun, use of sunscreen all of these could either enhance or
reduce serum 25(OH)D levels depending on their sun ex-
posure behaviours. We were unable to determine whether
race had an effect on increments in 25(OH)D levels due to
lack of information on physical characteristics such as skin
colour. Determinants of race such as skin colour are hard
to measure in general practice due to limited resources and
time required to undertake such tests [40]. Therefore we
were unable to undertake subgroup analysis to examine
the association between the race and variations in serum
25(OH)D levels following vitamin D supplementation. We
were unable to verify patients’ compliance to vitamin D
which may have led to variations in serum 25(OH)D levels.
Conclusions
Vitamin D deficiency is a crucial health disparity among
dark sinned migrants in Australia. Vitamin D synthesis
through the skin is limited in these migrants and the dietary
sources of vitamin D are also limited. High dose 50000 IU
vitamin D3, cholecalciferol remains a practical replacement
for low dose regimen in terms of efficacy and cost effective-
ness. Supplementation of high dose 50000 IU vitamin D3
to treat severe vitamin D deficiency is mandated in Victoria.It is timely that other states in Australia follow this example
to treat severe vitamin D deficiency among migrants as well
as Australian population. However currently there are
insufficient studies that have examined the efficacy of high
dose 50000 IU vitamin D supplementation in treating
VDD. Future randomised controlled trials that examine the
efficacy and safety of high dose vitamin D supplementation
in attaining sufficient serum 25(OH)D are required.
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